The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track companies developing breakthrough treatments through genomics, gene therapy, immunology, and personalized medicine technologies. This thematic healthcare ETF targets firms advancing precision medicine, cancer immunotherapy, genetic sequencing, and biotechnology innovations that could revolutionize patient care.
How It Works
IDNA uses a rules-based approach to identify companies deriving significant revenue from genomics, immunology, and advanced healthcare technologies. The fund employs modified market-cap weighting with screens for minimum market capitalization, liquidity, and revenue exposure to target themes. Holdings are rebalanced quarterly and include biotechnology firms, pharmaceutical companies, medical device manufacturers, and diagnostic companies. The portfolio typically holds 50-80 companies with concentration in developed markets, particularly the U.S.
Key Features
- Pure-play exposure to cutting-edge medical technologies including CRISPR gene editing, CAR-T cell therapy, and precision diagnostics
- Captures both established pharmaceutical giants and emerging biotech innovators developing next-generation treatments
- Launched in 2019 to capitalize on accelerating genomics revolution and personalized medicine adoption trends
Risks
- This ETF can lose significant value if clinical trials fail, regulatory approvals are denied, or breakthrough treatments prove ineffective, causing individual biotech stocks to plummet 50-80%
- Concentrated exposure to speculative biotechnology sector means higher volatility than broad healthcare ETFs, with potential for dramatic swings on drug development news
- Healthcare sector rotation risk during economic uncertainty when investors favor value over growth, potentially causing 20-30% declines in growth-oriented medical stocks
Who Should Own This
Best suited as a satellite holding (5-15% of portfolio) for aggressive growth investors with 5+ year time horizons and high risk tolerance. Appropriate for those seeking targeted exposure to medical innovation trends beyond traditional healthcare ETFs. Requires patience for long drug development cycles and ability to withstand biotech sector volatility.